Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Health CatalystHCAT -1.10%49 Debt-to-Equity is 1.24 as of Mar. 2026, which is 94% above its 10-year median of 0.64. GuruFocus rates HCAT with a GF Score™ of 49/100 and a GF Value™ of $4.98 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 559 Healthcare Providers & Services companies, Health Catalyst ranks worse than 78.53% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Health Catalyst's Debt-to-Equity or its related term are showing as below:
HCAT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.1 Med: 0.64 Max: 1.5
Current: 1.24
During the past 9 years, the highest Debt-to-Equity Ratio of Health Catalyst was 1.50. The lowest was -0.10. And the median was 0.64.
HCAT's Debt-to-Equity is ranked worse than 78.53% of 559
companies
in the Healthcare Providers & Services industry
Industry Median: 0.41
vs HCAT: 1.24
Health Catalyst (NAS:HCAT) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Health Catalyst Debt-to-Equity Related Terms
Health Catalyst Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Health Catalyst's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Health Catalyst's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Health Catalyst Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Health Catalyst's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Health Catalyst's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Health Catalyst (HCAT) has a Debt-to-Equity of 1.24 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Health Catalyst and its competitors. This is 94% above median its historical median of 0.64. According to the industry distribution chart, Health Catalyst ranks #439 out of 559 companies in the Healthcare Providers & Services industry, placing it in the top 78.5%.
Is Health Catalyst's Debt-to-Equity too high?
Health Catalyst's current Debt-to-Equity of 1.24 is 94% above median its 10-year median of 0.64. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. Health Catalyst's value of 1.24 is 202.4% above this industry median. Based on the distribution chart, Health Catalyst ranks #439 out of 559 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Health Catalyst has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Health Catalyst's Debt-to-Equity compare to SY and AMWL?
According to the Healthcare Providers & Services industry distribution chart, Health Catalyst ranks #439 out of 559 companies for Debt-to-Equity. This places Health Catalyst in the lower half of its industry. The industry median Debt-to-Equity is 0.41. Health Catalyst's value of 1.24 is 202.4% above this benchmark. While the company's 10-year median is 0.64 vs. the industry median of 0.41, Health Catalyst has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Health Catalyst's current Debt-to-Equity of 1.24 is 202.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Health Catalyst and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Health Catalyst's current Debt-to-Equity is 1.24, which is 94% above median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Health Catalyst stock overvalued right now?
Based on GuruFocus' analysis, Health Catalyst (HCAT) is currently considered Possible Value Trap. The stock's GF Value™ is $4.98, compared to a current price of $2.25 — trading 54.8% below its estimated fair value. The current Debt-to-Equity is 1.24, which is 94% above median its 10-year median of 0.64 and 202.4% above the Healthcare Providers & Services industry median of 0.41. Health Catalyst's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Health Catalyst (HCAT), the current Debt-to-Equity is 1.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Health Catalyst (HCAT) Overvalued in 2026?
Based on GuruFocus' analysis, Health Catalyst stock appears to be undervalued.
The current stock price of $2.25 is trading 54.8% below its estimated GF Value™ of $4.98.
GuruFocus considers Health Catalyst to be Possible Value Trap.
Key valuation signals for HCAT:
Debt-to-Equity: 1.24 (94% above median its 10-year median of 0.64)
GF Value™: $4.98 vs. price of $2.25 (54.8% below fair value)
Industry Position: 202.4% above the Healthcare Providers & Services median (#439 of 559)
No single metric tells the full story. See the HCAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
49GF Score
Get the complete analysis for HCAT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCAT has been successfully added to your 
